Abpro

Next-Generation Antibody Therapies

We develop our therapeutic candidates using our DiversImmune™ platform. Our antibody discovery platform enables us to generate antibodies against traditionally difficult targets. The resulting antibodies are high affinity, high specificity antibody “building blocks” with drug-like properties against a wide range of therapeutic targets. Our platform then enables us to assemble these building blocks into a variety of formats, tailored for each disease area.

We are focusing on areas where we can help mankind affected by serious disease and where monoclonal antibodies can play a leading role. This includes immuno-oncology/cancer, eye, infectious, and autoimmune disease.